SEC Form 4 · accession 0001193125-26-402815
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis Burrows
Officer — Chief Scientific Officer
Period of report
Sep 24, 2026
Accepted (ET)
Sep 25, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 24, 2026 | M | 30,000 | $6.15 | A | 63,053 | D | |
| Common StockF3 | Sep 24, 2026 | S | 20,726 | $10.8325 | D | 42,327 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $6.15 | Sep 24, 2026 | M | 30,000 | D | — | Jan 22, 2027 | Common stock | 30,000 | 0 | D |
Explanation of responses
- F1Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.
- F2Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
- F3This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This option is fully vested.